Decades-old University District dining staple abruptly closes
COLUMBUS, Ohio (WCMH) — Ohio State students will need to find a new late-night bite after a campus staple closed abruptly this week.
The familiar blue awning of Apollo's Greek Kitchen has greeted late-night diners for years, serving up gyros, hummus and fries. Established in 1975, the restaurant moved across from the Ohio Union from its original spot at the corner of 11th Avenue and High Street in 2000. The 50-year-old staple closed with little notice, but the storefront won't be empty for long.
Real estate company Sokol & Associates announced on Facebook that John Watson and Michael Will are moving their Burger Royale company into the spot. It will be their first storefront, as Burger Royale began as a Columbus food truck before expanding into a stall at Budd Dairy in September 2024.
Burger Royale works with a 'Pulp Fiction' theme, featuring 1950s throwback foods like hand-pressed burgers and fries cooked in duck fat. It left Budd Dairy Hall in early 2025 but still operates its food truck around the city.
Burger Royale has big shoes to fill at 1758 N. High St. With no announcement and its state operating license still active, it's unclear why Apollo's closed, or why so suddenly.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
AEye's Apollo Lidar Sensor Wins Prestigious AIIA Intelligent Perception Industry Leadership Award
PLEASANTON, Calif.--(BUSINESS WIRE)--AEye, Inc. (Nasdaq: LIDR), a global leader in adaptive, high-performance lidar solutions, announced today that its flagship 1550 nm lidar sensor, Apollo, has been honored with the Industry Leadership Award in the Intelligent Perception category at the AIIA2025 Automotive Intelligence Pilot Innovation Awards. 'Apollo combines precision, power, and flexibility to meet the evolving needs of the automotive industry and is critical to the widespread adoption of lidar. We are honored to receive this prestigious award, which reflects our commitment to innovation in intelligent perception technologies for autonomous and assisted driving. We are especially proud to be recognized by a leading trade organization in China, the world's largest market for lidar, underscoring AEye's position among the global leaders shaping the future of automotive intelligence,' said Matt Fisch, CEO at AEye. Apollo is distinguished among a competitive field of advanced lidar technologies by its unmatched performance, reliability, and adaptability in complex driving scenarios. Built on AEye's unique software-definable architecture, Apollo delivers long-range, high-resolution perception that powers safer, more intelligent mobility solutions. The AEye team is excited to showcase Apollo at EAC2025's Intelligent Driving and Embodied Intelligence Summit in Hangzhou, China from June 4 – 6 in Exhibition Hall 8 where attendees will be able to experience firsthand how AEye's next generation lidar is transforming autonomous and assisted driving. About AEye AEye's unique software-defined lidar solution enables advanced driver-assistance, vehicle autonomy, smart infrastructure, and logistics applications that save lives and propel the future of transportation and mobility. AEye's 4Sight™ Intelligent Sensing Platform, with its adaptive sensor-based operating system, focuses on what matters most: delivering faster, more accurate, and reliable information. AEye's 4Sight™ products, built on this platform, are ideal for dynamic applications which require precise measurement imaging to ensure safety and performance. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements within the meaning of the federal securities laws, including the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'continue,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'predict,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'potential,' 'seem,' 'seek,' 'outlook,' and similar expressions that predict or indicate future events or trends, or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements about Apollo's ability to meet the evolving needs of the automotive industry, Apollo's role in the widespread adoption of lidar, and Apollo's performance, among others. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are very difficult or impossible to predict and will differ from the assumptions. Many actual events and circumstances are beyond the control of AEye. Many factors could cause actual future events to differ from the forward-looking statements in this press release, including but not limited to: (i) the risks that Apollo's combination of precision, power, and flexibility may not meet the evolving needs of the automotive industry nor be critical to the widespread adoption of lidar to the extent or in the time frame anticipated, or at all; (ii) the risk that Apollo's performance, reliability, and adaptability in complex driving scenarios may be matched or exceeded by competitors or alternative technologies; (iii) the risks that Apollo may not deliver long-range, high-resolution perception that powers safer, more intelligent mobility solutions to the extent anticipated, or at all; (iv) the risks that AEye's products may not meet the diverse range of performance and functional requirements of target markets and customers; (v) the risks that AEye's products may not function as anticipated by AEye, or by target markets and customers; (vi) the risks that AEye may not be in a position to adequately or timely address either the near or long-term opportunities that may or may not exist in the evolving autonomous transportation industry; (vii) the risks that laws and regulations are adopted impacting the use of lidar that AEye is unable to comply with, in whole or in part; (viii) the risks associated with changes in competitive and regulated industries in which AEye operates, variations in operating performance across competitors, and changes in laws and regulations affecting AEye's business; (ix) the risks that AEye is unable to adequately implement its business plans, forecasts, and other expectations, and identify and realize additional opportunities; and (x) the risks of economic downturns and a changing regulatory landscape in the highly competitive and evolving industry in which AEye operates. These risks and uncertainties may be amplified by current or future global conflicts and current and potential trade restrictions, trade tensions, and tariffs, all of which continue to cause economic uncertainty. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the periodic report that AEye has most recently filed with the U.S. Securities and Exchange Commission, or the SEC, and other documents filed by us or that will be filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Investors are cautioned not to put undue reliance on forward-looking statements; AEye assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. AEye gives no assurance that AEye will achieve any of its expectations.
Yahoo
4 hours ago
- Yahoo
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate
ISS concludes that Apollo 'has not presented a compelling case for change' TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm' or the 'Company'), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services ('ISS') published a report on May 30, 2025 (the 'ISS Report') recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company's nominees for the Board of Directors (the 'Board') at the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the 'Meeting'). ISS is a leading independent proxy voting and corporate governance advisory firm whose recommendations are trusted by pension funds, investment managers, mutual funds, and other institutional shareholders. The ISS Report concludes: 'As the dissident has not presented a compelling case for change, shareholders are recommended to vote FOR all management nominees.' The ISS Report further recommended that MediPharm shareholders DO NOT VOTE on the gold dissident proxy card as Apollo did not provide a compelling case for change. Chris Taves, Chair of MediPharm, commented, 'We are very pleased that an independent proxy advisory firm has taken the time to meet with both parties to hear our respective arguments, and has recommended voting in favour of management's director nominees. Shareholders have been subjected to a large volume of information from both the Company and the dissident in recent weeks, and we believe the ISS Report reinforces our consistent position that Apollo has been flooding the market with misinformation and unsupportable statements. It is also encouraging that ISS has recognized the turnaround of our business that has been facilitated under the leadership of CEO David Pidduck. The Board truly believes that there is momentum in our business and that once we can overcome the costly distraction of this proxy contest, we can return our complete focus to strategic growth opportunities.' Key Conclusions in the ISS Report In explaining the reasons for its recommendation, the ISS Report reviews each of Apollo's major claims and concludes that there is insufficient evidence to support any of them. Statements in the ISS Report that refute Apollo's claims include the following: 'Since Q2 2022, quarterly revenues have more than doubled, adjusted EBITDA has swung from a $6.3 million loss to a $0.1 million gain, gross margins have expanded 50.9 percentage points over Q2 2022, and the company's SG&A has remained fairly stable. Against this backdrop, it is challenging to validate the dissident's claims that the company's costs have 'ballooned' or that revenue is 'imploding'. In particular, it also seems incorrect to suggest the company has experienced poor post-acquisition integration over a period where revenues and gross margins have risen dramatically while SG&A expenses have remained relatively flat.' 'LABS has experienced multiple years of improving financial results, which overlap with Pidduck's tenure as CEO as well as a series of acquisitions and non-core asset divestitures. Management has communicated a logical strategy that focuses on higher margin, international markets where the company can leverage a competitive advantage. Moreover, there does not appear to be sufficient evidence that the company is in imminent danger of running out of cash.' '… the company has generally outperformed peers and experienced a clear operational turnaround. Meanwhile, the dissident's assertions about the company's peril are not able to be sufficiently validated with available information. As such, the dissident has not presented a case for board change.' '… a review of [Total Shareholder Return] over [Pidduck's] tenure shows that the company has outperformed its peer group and [the Global X Marijuana Life Sciences Index ETF HMMJ] … There is limited utility focusing on absolute performance as the entire sector has suffered tremendous losses. In this context, it can be recognized that since 2022, LABS has managed to reverse course and separate itself positively from most peers.' 'Based on the company's improving financial performance since the VIVO acquisition and the manner in which redundant assets are being monetized to improve balance sheet strength, it is difficult to conclude that the company has engaged in reckless M&A.' 'The dissident has presented serious claims about concerns with the board's management oversight capabilities and executive compensation practices. At this time, there does not appear to be a conclusive deficiency in corporate governance and the company has provided valid explanations for its compensation practices.' The ISS Report summarizes the high standard required of any dissident seeking to replace an entire board of directors: 'When analyzing proxy contests, ISS focuses on two central questions: Has the dissident made a compelling case that change is warranted? If so, are the dissident nominees more likely to effect that change than the incumbent directors?' 'When the dissident is seeking board control, ISS looks for a well-reasoned and detailed business plan (including the dissident's strategic initiatives), a transition plan that describes how the change in control of the company will be effected, and where management continuity may be an issue, the identification of a qualified and credible new management team.' The ISS Report then reaches a clear conclusion on its recommendation for the election of directors: 'As there is no case for change at this time, shareholders are recommended to vote FOR all management nominees.' The ISS Report further recommends that shareholders vote for the resolution to fix the number of directors at seven, and vote for the resolution to approve MNP LLP as auditors and authorize the Board to fix their remuneration. The ISS Report also recommends that shareholders vote against the resolution to approve all unallocated awards under the Company's equity incentive plan. The independent Compensation Committee of the Board will continue to regularly review the Company's compensation policies. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting . You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, any potential momentum in the Company's business, the ability of the Company to capitalize on strategic growth opportunities, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Yahoo
20 hours ago
- Yahoo
Elon Musk Trying to Figure Out Who's to Blame for His Massive Unpopularity
As his time in DC disintegrated this week, Musk intimated to the Washington Post that he was very surprised by what he saw in American government — but not as surprised as he was by everyone's reaction. "The federal bureaucracy situation is much worse than I realized," the billionaire told the newspaper. "I thought there were problems, but it sure is an uphill battle trying to improve things in DC, to say the least." That "uphill battle" apparently included getting people on board with his Department of Government Efficiency (DOGE), the cost-cutting agency that Musk was seemingly gifted in exchange for his help getting Donald Trump elected. While the boy-brained billionaire wasn't exactly popular before his debut in American politics, he and his agency have become downright detested in 2025. From its iffy mandate and its enormous failure to reach its savings goals to its massive professional and competence breaches, DOGE has been a major dud — and Musk's companies are bearing the brunt. But ask Musk, and he has no idea why everybody is so mad. As he told it to WaPo, the agency mysteriously became the "whipping boy for everything." "Something bad would happen anywhere," Musk said, "and we would get blamed for it even if we had nothing to do with it." Despite his attempts at a breezy reboot this week, it's clear the uber-wealthy memelord is aware that the public hates him and his politics — but the alleged "free speech absolutist" can't seem to figure out why people would want to take their righteous anger out on his company's cars. "People were burning Teslas," he lamented. "Why would you do that? That's really uncool." This isn't the first time Musk has searched around dumbfounded, like a confused John Travolta in "Pulp Fiction," looking for the reason people are taking their anger out Teslas. In March, the world's sometimes-richest man took to the social network he purchased to claim that an "investigation" had found five individuals, along with a liberal-leaning fundraising platform, were behind the widespread protests against his electric vehicle company. He didn't acknowledge, of course, the crux of those protests: that even Republicans and former fanboys consider the mass firing of civil servants toxic, and that his own poor approval ratings were bringing down Trump's. Despite his unceremonious exit from government, DOGE's work will go on in Musk's stead, and the agency will soon be "tackling projects with the highest gain for the pain, which still means a lot of good things in terms of reducing waste and fraud." Today in Washington, as in South Texas, it's business as usual as the White House prepares to send a new slew of DOGE cuts to Congress in a spending bill and SpaceX launches more than two dozen Starlink satellites aboard a Falcon 9 rocket. Life in DC has gone on after Musk has left the building — not with a bang, but with a whimper. More on Musk: You Can Suddenly Sense Elon Musk's Desperation
